[
    [
        {
            "time": "2023-10-05",
            "original_text": "Is Eli Lilly (LLY) Stock A Buy or Sell?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "LLY",
                    "Buy",
                    "Sell"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Is Eli Lilly (LLY) Stock A Buy or Sell?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Pfizer/Eli Lilly's Tanezumab Safety Profile Fails To Impress FDA Even After 15 Years Of Development Across 41 Trials",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Eli Lilly",
                    "Tanezumab",
                    "FDA",
                    "Safety Profile",
                    "Development"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Pfizer/Eli Lilly's Tanezumab Safety Profile Fails To Impress FDA Even After 15 Years Of Development Across 41 Trials",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Buy-the-Dip Candidates: Buy Penn National Gaming",
            "features": {
                "keywords": [
                    "Buy-the-Dip",
                    "Penn National Gaming"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "gaming",
                    "entertainment"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Buy-the-Dip Candidates: Buy Penn National Gaming",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]